Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Sinopharm Modern: Wholly owned subsidiary provides guarantees to its affiliated company
Everyday AI News, China National Pharmaceutical Modern (SH 600420, closing price: 10.36 yuan) announced on the evening of March 27 that, after the review and approval of the 20th meeting of the 8th board of directors, the company will provide a joint liability guarantee of 400 million yuan for its wholly-owned subsidiary, China National Pharmaceutical Jiangsu Weiqida, with a guarantee period of 18 months. As of December 31, 2025, the company’s external guarantee balance is 86.8894 million yuan, all of which are guarantees for China National Pharmaceutical Jiangsu Weiqida, accounting for 0.63% of the net assets attributable to the shareholders of the listed company at the end of 2025. As of now, the aforementioned guarantee is nearing expiration. In order to further meet the business development and daily operational needs of China National Pharmaceutical Jiangsu Weiqida, according to the China Securities Regulatory Commission’s “Guidance No. 8 for Regulating Listed Companies—Regulatory Requirements for Fund Transactions and External Guarantees of Listed Companies,” the “Articles of Association,” and other laws, regulations, and normative documents, the company’s wholly-owned subsidiary, China National Pharmaceutical Weiqida, will provide guarantees for its subsidiary, China National Pharmaceutical Jiangsu Weiqida, with a guarantee amount not exceeding 320 million yuan, and the above guarantees will be valid for 18 months from the date of this board meeting’s approval.
On March 26, the company held the 3rd meeting of the 9th board of directors, which reviewed and approved the proposal on the wholly-owned subsidiary providing guarantees for its affiliated enterprise, with 9 votes in favor, 0 votes against, and 0 abstentions. According to the relevant provisions of the “Shanghai Stock Exchange Listing Rules” and the “Articles of Association,” the guarantee amount is within the scope of the board of directors’ review and does not need to be submitted to the shareholders’ meeting for review.
After the implementation of this guarantee, the maximum external guarantee balance of the company and its controlled subsidiaries will be 320 million yuan, accounting for 2.32% of the net assets attributable to the shareholders of the listed company at the end of 2025.
Everyday Economic News (nbdtoutiao) — The US-Iran war is “devouring” the profits of Shandong’s refinery companies, with a loss of 153 yuan for processing a ton! Previously saving 20 dollars per barrel, now oil prices over a hundred have returned to zero overnight.
(Reporter Wang Xiaobo)
Disclaimer: The content and data in this article are for reference only and do not constitute investment advice. Please verify before use. Risks are borne by the user.
Daily Economic News